Ducommun Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Ducommun (NYSE:DCO) posted Q1 earnings of $5.23 million, an increase from Q4 of…

Pulled from Benzinga Pro data, Ducommun (NYSE:DCO) posted Q1 earnings of $5.23 million, an increase from Q4 of 35.27%. Sales dropped to $181.19 million, a 3.76% decrease between quarters. In Q4, Ducommun earned $8.08 million, and total sales reached $188.27 million.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Ducommun posted an ROCE of 0.01%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Ducommun is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Ducommun, the positive return on capital employed ratio of 0.01% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Ducommun reported Q1 earnings per share at $0.63/share, which beat analyst predictions of $0.6/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Castle Biosciences Announces Preliminary Q4 And FY23 Results; Expects To Deliver More Than $210M For FY23 Total Revenue Vs $203.95M Est.; Year-End 2023 Cash, Cash Equivalents And Marketable Investment Securities Expected To Be ~$243M

Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022Year-end 2023 cash, cash equivalents and

CSTL